Cargando…

Identification of long non-coding RNA-mediated transcriptional dysregulation triplets reveals global patterns and prognostic biomarkers for ER(+)/PR(+), HER2(−) and triple negative breast cancer

Breast cancer (BRCA) is the most common type of cancer in adult females. Estrogen receptor (ER)(+)/progesterone receptor (PR)(+), human epidermal-growth factor receptor 2 (HER2)(−) BRCA and triple-negative breast cancer (TNBC) are two important subtypes of this disease. Long non-coding RNA (lncRNA)-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Zhengwei, Gao, Wei, Sun, Jiayi, Li, Yujing, Sun, Yu, Chen, Tong, Ge, Shuke, Guo, Wenbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657959/ https://www.ncbi.nlm.nih.gov/pubmed/31257479 http://dx.doi.org/10.3892/ijmm.2019.4261

Ejemplares similares

ODP433 An increased in AIPB expression in Triple Negative (ER-/PR-/Her2-) Breast Tumors reduces estradiol synthesis
por: Downs, William V, et al.
Publicado: (2022)

THU555 Stress Induced AIPB Expression In Triple Negative (ER-/PR-/Her2-) Breast Tumors Reduces Estradiol
por: Patrawala, Mahjabin, et al.
Publicado: (2023)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
por: Xie, Peiling, et al.
Publicado: (2021)

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
por: Xu, Junnan, et al.
Publicado: (2018)

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017)

ODP539 AIPB is a Biomarker for ER+/PR+/Her2- Breast Cancers
por: Cubbedge, Chandler, et al.
Publicado: (2022)

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

3D Visualization of the Dynamic Bidirectional Talk Between ER/PR and Her2 Pathways
por: Lyv, Jiahong, et al.
Publicado: (2021)

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)

The Association between ER, PR, HER2, and ER−/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database
por: Shao, Hong Yu, et al.
Publicado: (2023)

Weight Loss Intervention in Survivors of ER/PR-negative Breast Cancer
por: Vitolins, Mara Z, et al.
Publicado: (2014)

Pituitary, Gonadal, Thyroid Hormones and Endocrine Disruptors in Pre and Postmenopausal Nigerian Women with ER-, PR- and HER-2-Positive and Negative Breast Cancers
por: Ajayi, Olulope, et al.
Publicado: (2018)

BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma
por: Kumar, Mohit, et al.
Publicado: (2017)

Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review
por: Kandula, Mahesh, et al.
Publicado: (2013)

A code for optimising triplet layout
por: Van Riesen-Haupt, Leon, et al.
Publicado: (2017)

Association between Acquired Uniparental Disomy and Homozygous Mutations and HER2/ER/PR Status in Breast Cancer
por: Tuna, Musaffe, et al.
Publicado: (2010)

The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes
por: Parise, Carol A., et al.
Publicado: (2015)

Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
por: Chen, Chih-Jung, et al.
Publicado: (2022)

Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
por: Schlotman, Alyssa, et al.
Publicado: (2020)

Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast Carcinoma
por: Ahmed, Hussain Gadelkarim, et al.
Publicado: (2011)

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer
por: Bauer, Katrina, et al.
Publicado: (2010)

Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study
por: Hussein, Israa A, et al.
Publicado: (2020)

Digital Validation of Breast Biomarkers (ER, PR, AR and HER2) in Cytology Specimens Using Three Different Scanners
por: Salama, Abeer M., et al.
Publicado: (2021)

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (−) Breast Cancer
por: Du, Feng, et al.
Publicado: (2022)

fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions
por: Soares, Maria, et al.
Publicado: (2022)

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance
por: Hu, Xueyang, et al.
Publicado: (2023)

Epigenetic Dysregulation of KCNK9 Imprinting and Triple-Negative Breast Cancer
por: Skaar, David A., et al.
Publicado: (2021)

Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
por: Peterlongo, Paolo, et al.
Publicado: (2021)

Is oestrogen receptor-negative/progesterone receptor-positive (ER−/PR+) a real pathological entity?
por: Onitilo, Adedayo A, et al.
Publicado: (2021)

Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
por: Puri, Vandana, et al.
Publicado: (2011)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

Deep learned tissue “fingerprints” classify breast cancers by ER/PR/Her2 status from H&E images
por: Rawat, Rishi R., et al.
Publicado: (2020)

Expression of MTDH and IL-10 Is an Independent Predictor of Worse Prognosis in ER-Negative or PR-Negative Breast Cancer Patients
por: Chu, Pei-Yi, et al.
Publicado: (2020)

Codon Size Reduction as the Origin of the Triplet Genetic Code
por: Baranov, Pavel V., et al.
Publicado: (2009)

Fitting the standard genetic code into its triplet table
por: Yarus, Michael
Publicado: (2021)

Function of miR-152 as a Tumor Suppressor in Human Breast Cancer by Targeting PIK3CA
por: Ge, Shuke, et al.
Publicado: (2017)

Carvacrol: An In Silico Approach of a Candidate Drug on HER2, PI3Kα, mTOR, hER-α, PR, and EGFR Receptors in the Breast Cancer
por: Herrera-Calderon, Oscar, et al.
Publicado: (2020)

Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers
por: Parise, Carol A., et al.
Publicado: (2014)

Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling
por: Dai, Xiaofeng, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1u9laomrbq9n7i34rc86ondkml